Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
š¼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Mylan NV (MYL US)
Watchlist
57
Analysis
Health Care
ā¢
United States
Mylan NV is a global generic and specialty pharmaceuticals company. The Company operates an active pharmaceutical ingredient manufacturer and runs a specialty business focused on respiratory, allergy, and psychiatric therapies.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
ā¢
Thematic (Sector/Industry)
ā¢
09 Aug 2016 18:52
A 'heads Up' on Changing World Heights
A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest...
Bixmoor
350 Views
Share
bullish
ā¢
Thematic (Sector/Industry)
ā¢
07 Jul 2016 10:21
No Pain, Potential for Lots of Gain for Pfizer, Lilly, and Regeneron
The history of pain drugs that target nerve growth factor has been a roller-coaster ride for drug developers and investors. In 2010, expectations...
Morningstar, Inc.
304 Views
Share
bullish
ā¢
Thematic (Sector/Industry)
ā¢
15 Apr 2016 11:33
Healthcare Observer:Ā Orthopedic Innovation Beyond Large Joint Market Fuels Long-Term Growth
Over the next decade, we expect orthopedic innovation in extremities, robotics, and 3-D printing to be key drivers of growth as fee-for-value...
Morningstar, Inc.
353 Views
Share
bullish
ā¢
Thematic (Sector/Industry)
ā¢
22 Jan 2016 15:52
Low Odds of U.S. Drug Pricing Reforms Create Favorable Valuations
Democratic presidential candidates' potential drug policy reforms have pressured drug stocks, and ongoing political campaigns are likely to...
Morningstar, Inc.
1.7k Views
Share
bullish
ā¢
Thematic (Sector/Industry)
ā¢
12 Nov 2015 09:34
Healthcare Observer: As Long-Term Patent Exposure Ebbs, Innovation in Big Pharma Pipelines Support
Pipeline innovation outpacing patent losses represents a core element of the wide moat ratings for most of the Big Pharma firms. Slowing patent...
Morningstar, Inc.
488 Views
Share
First
Previous
3
4
5
6
7
8
9
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright Ā© 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x